2026-09-19T15:47:56Z https://api.figshare.com/v2/oai

oai:figshare.com:article/30426514 2025-08-01T00:00:00Z portal_693 item_type_8 month_year_08_2025

Engineered Anti-CD40 Agonist Antibody for Cancer Vaccine Delivery Dahee Jung (3357377) Health Sciences Immunology Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic–monovalent streptavidin fusion antibody (αCD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). αCD40-mSAs were validated for mSA expression and demonstrated strong binding affinities to mouse CD40 and biotin. Advanced imaging demonstrated that αCD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of αCD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with αCD40-mSAs elicited robust cancer-specific CD8⁺ T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support αCD40-mSAs as an 'all-in-one' vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination. 2025-08-01T00:00:00Z Text Thesis 10.25417/uic.30426514.v1 https://figshare.com/articles/thesis/Engineered_Anti-CD40_Agonist_Antibody_for_Cancer_Vaccine_Delivery/30426514 In Copyright Open Access after 2027-09-01